Cargando…

Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry()

BACKGROUND: The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes. This study compares peri-procedural results of LAAO with Watchman FLX (Boston Scientific, Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-González, Ignacio, Torres Saura, Francisco, Trejo-Velasco, Blanca, Antonio Fernández Díaz, José, Fajardo Molina, Ricardo, del Valle-Fernández, Raquel, Moreno Terribas, Gerardo, Martí Sánchez, David, López-Mínguez, José-Ramón, Gomez-Blazquez, Ivan, Sanmartin Pena, Juan-Carlos, Botas, Javier, Martin Lorenzo, Pedro, Palazuelos, Jorge, Albarrán Rincon, Ramón, Mohandes, Mohsen, Rodriguez Entem, Felipe-Jose, Martí, Gerard, Valero, Ernesto, Gutiérrez, Hipólito, Amat-Santos, Ignacio J., Nombela-Franco, Luis, Salinas, Pablo, Teruel, Luis, Gomez-Hospital, Joan-Antoni, Arzamendi, Dabit, Torres Sanabria, Mario, Calle Pérez, Germán, Cañadas Pruaño, Dolores, Pérez de Prado, Armando, Benito González, Tomás, Arroyo-Úcar, Eduardo, Estévez-Loureiro, Rodrigo, Caneiro-Queija, Berenice, Ibañez Criado, Jose L., Ruiz-Nodar, Juan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728396/
https://www.ncbi.nlm.nih.gov/pubmed/35024431
http://dx.doi.org/10.1016/j.ijcha.2021.100941
Descripción
Sumario:BACKGROUND: The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes. This study compares peri-procedural results of LAAO with Watchman FLX (Boston Scientific, Marlborough, Massachusetts) in centers with varying degrees of experience with the Watchman 2.5 and Watchman FLX. METHODS: Prospective, multicenter, “real-world” registry including consecutive patients undergoing LAAO with the Watchman FLX at 26 Spanish sites (FLX-SPA registry). Implanting centers were classified according to the center’s prior experience with the Watchman 2.5. A further division of centers according to whether or not they had performed ≤ 10 or > 10Watchman FLX implants was prespecified at the beginning of the study. Procedural outcomes of institutions stratified according to their experience with the Watchman 2.5 and FLX devices were compared. RESULTS: 359 patients [mean age 75.5 (SD8.1), CHA(2)DS(2)-VASc 4.4 (SD1.4), HAS-BLED 3.8(SD0.9)] were included. Global success rate was 98.6%, successful LAAO with the first selected device size was achieved in 95.5% patients and the device was implanted at first attempt in 78.6% cases. There were only 9(2.5%) major peri-procedural complications. No differences in efficacy or safety results according to the centeŕs previous experience with Watchman 2.5 and procedural volume with Watchman FLX existed. CONCLUSIONS: The Watchman FLX attains high procedural success rates with complete LAA sealing in unselected, real-world patients, along with a low incidence of peri-procedural complications, regardless of operatoŕs experience with its previous device iteration or the number of Watchman FLX devices implanted.